Free Trial

Artiva Biotherapeutics (ARTV) Competitors

Artiva Biotherapeutics logo
$5.41 +0.57 (+11.78%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$5.20 -0.21 (-3.88%)
As of 10/24/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARTV vs. MLTX, NAGE, OPT, BCYC, KROS, ARCT, KALV, ESPR, INBX, and PRTA

Should you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include MoonLake Immunotherapeutics (MLTX), Niagen Bioscience (NAGE), Opthea (OPT), Bicycle Therapeutics (BCYC), Keros Therapeutics (KROS), Arcturus Therapeutics (ARCT), KalVista Pharmaceuticals (KALV), Esperion Therapeutics (ESPR), Inhibrx Biosciences (INBX), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry.

Artiva Biotherapeutics vs. Its Competitors

Artiva Biotherapeutics (NASDAQ:ARTV) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Artiva Biotherapeutics currently has a consensus target price of $18.25, suggesting a potential upside of 237.34%. MoonLake Immunotherapeutics has a consensus target price of $36.00, suggesting a potential upside of 278.15%. Given MoonLake Immunotherapeutics' higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Artiva Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artiva Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
MoonLake Immunotherapeutics
2 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.07

In the previous week, MoonLake Immunotherapeutics had 21 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 32 mentions for MoonLake Immunotherapeutics and 11 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.69 beat MoonLake Immunotherapeutics' score of 0.12 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Artiva Biotherapeutics
3 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MoonLake Immunotherapeutics
2 Very Positive mention(s)
2 Positive mention(s)
25 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Artiva Biotherapeutics has higher revenue and earnings than MoonLake Immunotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artiva Biotherapeutics$250K528.67-$65.37MN/AN/A
MoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.78-3.42

Artiva Biotherapeutics has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

MoonLake Immunotherapeutics' return on equity of -40.98% beat Artiva Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Artiva BiotherapeuticsN/A -42.60% -37.76%
MoonLake Immunotherapeutics N/A -40.98%-35.81%

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 21.4% of Artiva Biotherapeutics shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Artiva Biotherapeutics beats MoonLake Immunotherapeutics on 7 of the 12 factors compared between the two stocks.

Get Artiva Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARTV vs. The Competition

MetricArtiva BiotherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$118.22M$3.43B$6.23B$10.66B
Dividend YieldN/A2.27%5.71%4.82%
P/E RatioN/A25.1230.4330.34
Price / Sales528.67507.39595.82134.75
Price / CashN/A45.5737.0161.44
Price / Book0.7010.4012.046.60
Net Income-$65.37M-$52.62M$3.32B$276.82M
7 Day Performance-9.98%2.09%1.88%2.53%
1 Month Performance79.73%12.32%7.68%3.71%
1 Year Performance-48.28%14.12%56.01%33.82%

Artiva Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARTV
Artiva Biotherapeutics
3.9105 of 5 stars
$5.41
+11.8%
$18.25
+237.3%
-46.8%$118.22M$250K0.0081Gap Up
MLTX
MoonLake Immunotherapeutics
2.8943 of 5 stars
$9.35
+2.5%
$36.00
+285.0%
-79.4%$585.79MN/A-3.362Trending News
NAGE
Niagen Bioscience
2.3224 of 5 stars
$7.21
-1.6%
$13.42
+86.1%
N/A$584.59M$99.60M34.33120
OPT
Opthea
0.4522 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
-18.8%$583.10M$30K0.008News Coverage
Gap Up
High Trading Volume
BCYC
Bicycle Therapeutics
3.4375 of 5 stars
$8.16
-0.1%
$22.22
+172.3%
-68.2%$566.23M$35.28M-2.32240Upcoming Earnings
KROS
Keros Therapeutics
3.0596 of 5 stars
$15.19
+9.8%
$30.00
+97.5%
-74.7%$561.71M$3.55M49.00100High Trading Volume
ARCT
Arcturus Therapeutics
3.4594 of 5 stars
$21.51
+4.1%
$50.57
+135.1%
-40.9%$561.02M$109.80M-9.65180Trending News
Analyst Downgrade
KALV
KalVista Pharmaceuticals
3.8146 of 5 stars
$11.54
+4.0%
$26.43
+129.0%
-7.8%$560.81MN/A-2.93100
ESPR
Esperion Therapeutics
3.734 of 5 stars
$2.82
+2.5%
$7.00
+148.2%
+31.6%$554.46M$332.31M-5.76200
INBX
Inhibrx Biosciences
2.0544 of 5 stars
$38.22
+2.6%
N/A+272.7%$539.58M$200K-3.61166Trending News
Gap Up
PRTA
Prothena
2.693 of 5 stars
$10.37
+4.5%
$20.50
+97.7%
-39.6%$533.99M$10.34M-1.84130Positive News

Related Companies and Tools


This page (NASDAQ:ARTV) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners